Neurophet Brings AI Brain Imaging Software to Raffles Hospital
Source: Korea Biomedical Review
Korean AI firm Neurophet has signed a contract to supply its brain neurodegeneration imaging analysis software, Neurophet AQUA, to Singapore's Raffles Hospital via a SaaS model. The deployment marks Neurophet's first expansion into Singapore's private hospital sector after earlier installations at NUS, NTU, and SGH.
Korean AI-powered brain imaging company Neurophet is expanding deeper into Singapore's healthcare sector, signing a contract to supply its neurodegeneration analysis software Neurophet AQUA to Raffles Hospital. The software, delivered as a Software-as-a-Service (SaaS) solution, uses artificial intelligence to perform ultra-fast quantitative analysis of brain MRI scans, assessing brain atrophy and white matter abnormalities linked to Alzheimer's disease and vascular dementia.
Neurophet AQUA generates personalised analytical reports that quantify structural changes associated with neurodegenerative disorders, helping clinicians track disease progression and treatment response with greater precision. The SaaS delivery model is expected to generate stable recurring revenue for Neurophet while giving Raffles Hospital access to cutting-edge AI diagnostics without upfront infrastructure costs.
This contract follows prior deployments at Singapore's public healthcare and research institutions, including the Dementia Research Center at Nanyang Technological University, the National University of Singapore, and Singapore General Hospital. Raffles Hospital, the flagship of Raffles Medical Group, is one of Singapore's leading private tertiary hospitals and a major international medical hub attracting patients from across Asia.
The partnership gives Neurophet a marquee private-sector reference site in Singapore, which the company expects will accelerate broader adoption across Southeast Asia. Raffles Medical Group operates over 100 clinics and healthcare facilities with expanding overseas presence in China, Japan, and Vietnam, opening the door for deeper integration of Neurophet's AI tools across the network.
Why it matters for Singapore: Singapore's ambition to become Asia's leading healthcare hub depends in part on early adoption of AI-driven diagnostics. Neurophet's expansion from public research institutions into the private hospital sector signals growing confidence in AI-powered medical imaging among Singapore's healthcare providers. For a city-state facing an ageing population and rising dementia prevalence, tools that enable earlier and more accurate diagnosis of neurodegenerative conditions could meaningfully improve patient outcomes while reducing the long-term burden on the healthcare system.